US pharma major Eli Lilly (NYSE: LLY) and biotech Incyte (Nasdaq: INCY) have announced new data on rheumatoid arthritis (RA) patients treated with baricitinib showing improved in quality of life and other positive outcomes compared to methotrexate or adalimumab, a big-seller sold by USA-based drugmaker AbbVie (NYSE: ABBV) as Humira.
The findings from Phase III studies, which back up earlier data, were presented at the Annual European Congress of Rheumatology (EULAR 2016) this week, and also showed that baricitinib patients demonstrated improved productivity at work.
In these studies, significant improvements in patient-reported measures, including pain, physical function, tiredness and morning joint stiffness, were observed as early as one week after initial treatment with baricitinib.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze